Q1 Earnings Estimate for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of TG Therapeutics in a research note issued on Tuesday, March 4th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings of $0.21 per share for the quarter. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2026 earnings at $1.73 EPS.

Several other research analysts have also weighed in on TGTX. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. Finally, HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Up 2.1 %

TG Therapeutics stock traded up $0.79 during midday trading on Thursday, hitting $39.23. 4,876,845 shares of the stock were exchanged, compared to its average volume of 2,612,308. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $40.31. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market cap of $6.16 billion, a P/E ratio of -392.26 and a beta of 2.30. The company has a 50 day moving average price of $31.07 and a two-hundred day moving average price of $28.57.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System lifted its position in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the last quarter. Blue Trust Inc. increased its stake in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the period. Summit Investment Advisors Inc. lifted its position in shares of TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 463 shares during the period. Private Advisor Group LLC lifted its position in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after acquiring an additional 542 shares during the period. Finally, Brookstone Capital Management grew its holdings in shares of TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after purchasing an additional 624 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.